hdac inhibitor saha Search Results


hdac inhibitors saha  (Enzo Biochem)
90
Enzo Biochem hdac inhibitors saha
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Hdac Inhibitors Saha, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/hdac+inhibitors+saha/pmc08002291-335-16-25
Average 90 stars, based on 1 article reviews
hdac inhibitors saha - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hdac inhibitor suberoylanilide hydroxamic acid (saha)  (INDOFINE Inc)
90
INDOFINE Inc hdac inhibitor suberoylanilide hydroxamic acid (saha)
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Hdac Inhibitor Suberoylanilide Hydroxamic Acid (Saha), supplied by INDOFINE Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/hdac+inhibitor+suberoylanilide+hydroxamic+acid++saha+/us11976069-559-0-9
Average 90 stars, based on 1 article reviews
hdac inhibitor suberoylanilide hydroxamic acid (saha) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
sirt2/hdac inhibitor 46  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals sirt2/hdac inhibitor 46
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Sirt2/Hdac Inhibitor 46, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/saha+derived+multitarget+sirt2+hdac+inhibitor+46/pm37902787-99-3-4
Average 90 stars, based on 1 article reviews
sirt2/hdac inhibitor 46 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hdac inhibitors saha  (ALTANA Inc)
90
ALTANA Inc hdac inhibitors saha
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Hdac Inhibitors Saha, supplied by ALTANA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/hdac+inhibitors+saha/pm17455259-46-0-13
Average 90 stars, based on 1 article reviews
hdac inhibitors saha - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hdac inhibitor saha  (Merck KGaA)
90
Merck KGaA hdac inhibitor saha
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Hdac Inhibitor Saha, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/hdac+inhibitor+saha/pmc04210916-291-3-22
Average 90 stars, based on 1 article reviews
hdac inhibitor saha - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hdac inhibitor saha  (Aton Pharma Inc)
90
Aton Pharma Inc hdac inhibitor saha
HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and <t>SAHA)</t> showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.
Hdac Inhibitor Saha, supplied by Aton Pharma Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hdac+inhibitor+saha/hdac+inhibitor+saha/pm15155736-184-32-19
Average 90 stars, based on 1 article reviews
hdac inhibitor saha - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and SAHA) showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.

Journal: International Journal of Molecular Sciences

Article Title: High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors

doi: 10.3390/ijms22063022

Figure Lengend Snippet: HTS for CEBPD -modulating compounds and identification of hits. ( a ) A schematic drawing of the developed screening assay in THP-1 reporter Mϕ using SEAP reporter. ( b , c ) Here, we show the hit-contained screening plate from the LOPAC ® ( b ) and the hit-containing screening plate from the ENZO ® ( c ) compound libraries. The primary screening data from all plates is summarized in . PMA-differentiated THP-1 reporter Mϕ were not treated (M0), pre-treated with 0.001% ( v / v ) DMSO (solvent control), 10 μM compound from LOPAC ® (b) and ENZO ® (c) libraries, or 0.5 μM TSA for 1 h and stimulated (M1) with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (read 1 and 2). Hit compounds (I-BET151, Ro 11-1464, and SAHA) showing a strong activatory effect on SEAP secretion were identified in areas >3 SDs (m + 3 × SD, black line) of an average signal (m, read line), calculated for the corresponding “M1, DMSO” condition. For read 2, CV was calculated for M0 and M1 DMSO controls (b: 48.9% and 27.7%, respectively; c: 36.6% and 44.4%, respectively). The corresponding Z´-factor was −0.4 (b) and −1.3 (c). RLU: relative luminescence units.

Article Snippet: In conclusion, this study identified the BET inhibitors I-BET151 and Ro 11-1464 as well as the HDAC inhibitors SAHA and TSA from LOPAC ® and ENZO ® libraries as potent CEBPD -modulating compounds in LPS- and IFN-γ-stimulated THP-1 reporter Mφ.

Techniques: Screening Assay, Solvent, Control, SEAP Assay

The effect of HDAC inhibitors SAHA and TSA on SEAP secretion and mRNA expression. In ( a ), PMA-differentiated THP-1 reporter Mϕ were pre-treated with 10 μM SAHA or 0.5 μM TSA for 1 h and stimulated with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (mean ± SD, n = 3 with 2 wells per condition). Changes in SEAP enzymatic activity were analyzed relative to M1 DMSO control via Brown–Forsythe and Welch ANOVA test with Dunnett’s correction for multiple comparisons; n.s.: not significant; * p < 0.05. In ( b – f ), PMA-differentiated THP-1 reporter Mϕ were pre-treated with 10 μM SAHA or 0.5 μM TSA for 1 h and stimulated with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 4 h for mRNA expression analysis of reporter CEBPD::SEAP ( b ), endogenous CEBPD ( c ), IL-6 ( d ), CCL2 ( e ), and IL-1ß ( f ) (median and range, n = 3 with 2 wells per condition). mRNA expression analysis was performed via qRT-PCR (ΔΔCt method) using RPL37A as an internal reference gene. Fold change in mRNA expression is displayed relative to M0 control, set as 1. The compound-mediated changes in mRNA expression were analyzed relative to M1 DMSO control via ordinary one-way ANOVA (for normally distributed data and equal SDs), Brown–Forsythe and Welch ANOVA test with Dunnett’s correction (for normally distributed data and different SDs), or Kruskal-Wallis test with Dunn´s correction for multiple comparisons (for non-normally distributed data). * p < 0.05; ** p < 0.005; *** p < 0.001.

Journal: International Journal of Molecular Sciences

Article Title: High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors

doi: 10.3390/ijms22063022

Figure Lengend Snippet: The effect of HDAC inhibitors SAHA and TSA on SEAP secretion and mRNA expression. In ( a ), PMA-differentiated THP-1 reporter Mϕ were pre-treated with 10 μM SAHA or 0.5 μM TSA for 1 h and stimulated with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 24 h for SEAP assay (mean ± SD, n = 3 with 2 wells per condition). Changes in SEAP enzymatic activity were analyzed relative to M1 DMSO control via Brown–Forsythe and Welch ANOVA test with Dunnett’s correction for multiple comparisons; n.s.: not significant; * p < 0.05. In ( b – f ), PMA-differentiated THP-1 reporter Mϕ were pre-treated with 10 μM SAHA or 0.5 μM TSA for 1 h and stimulated with 0.1 µg/mL LPS + 20 ng/mL IFN-γ for 4 h for mRNA expression analysis of reporter CEBPD::SEAP ( b ), endogenous CEBPD ( c ), IL-6 ( d ), CCL2 ( e ), and IL-1ß ( f ) (median and range, n = 3 with 2 wells per condition). mRNA expression analysis was performed via qRT-PCR (ΔΔCt method) using RPL37A as an internal reference gene. Fold change in mRNA expression is displayed relative to M0 control, set as 1. The compound-mediated changes in mRNA expression were analyzed relative to M1 DMSO control via ordinary one-way ANOVA (for normally distributed data and equal SDs), Brown–Forsythe and Welch ANOVA test with Dunnett’s correction (for normally distributed data and different SDs), or Kruskal-Wallis test with Dunn´s correction for multiple comparisons (for non-normally distributed data). * p < 0.05; ** p < 0.005; *** p < 0.001.

Article Snippet: In conclusion, this study identified the BET inhibitors I-BET151 and Ro 11-1464 as well as the HDAC inhibitors SAHA and TSA from LOPAC ® and ENZO ® libraries as potent CEBPD -modulating compounds in LPS- and IFN-γ-stimulated THP-1 reporter Mφ.

Techniques: Expressing, SEAP Assay, Activity Assay, Control, Quantitative RT-PCR

Fold change (mean ± SD) for mRNA expression in SAHA-pre-treated and TSA-pre-treated target cells compared to M0 controls ( compare <xref ref-type= Figure 6 )." width="100%" height="100%">

Journal: International Journal of Molecular Sciences

Article Title: High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors

doi: 10.3390/ijms22063022

Figure Lengend Snippet: Fold change (mean ± SD) for mRNA expression in SAHA-pre-treated and TSA-pre-treated target cells compared to M0 controls ( compare Figure 6 ).

Article Snippet: In conclusion, this study identified the BET inhibitors I-BET151 and Ro 11-1464 as well as the HDAC inhibitors SAHA and TSA from LOPAC ® and ENZO ® libraries as potent CEBPD -modulating compounds in LPS- and IFN-γ-stimulated THP-1 reporter Mφ.

Techniques: Expressing